EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus

Richard A Furie, Maria Dall'Era, Edward M Vital, Jay P Garg, Fedra Irazoque Palazuelos, Adolfina E Zuta Santillán, Jorge Ravelo-Hernández, Mittermayer B Santiago, Beatriz Zazueta Montiel, Stella Botha, Piotr Leszczyński, Viviane Angelina de Souza und 14 weitere

New England Journal of Medicine · 16.07.2026 · 395 (3) · 243-254

DOI: 10.1056/nejmoa2516150 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 16.07.2026. Verfasst von Richard A Furie und 25 weiteren Autor:innen. Beteiligte Einrichtung: Northwell, New Hyde Park, NY. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: F. Hoffmann-La Roche Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLupus Erythematosus, SystemicAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodSeverity of Illness IndexAntigens, CD20Treatment OutcomeAged

Substanzen

Antibodies, Monoclonal, HumanizedobinutuzumabAntigens, CD20

Autor:innen und Institutionen

  • Northwell, New Hyde Park, NY.
  • Division of Rheumatology, Northwell, Great Neck, NY.
  • University of California, San Francisco, San Francisco.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
  • National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
  • Genentech, South San Francisco, CA.

Förderung

  • F. Hoffmann-La Roche Ltd.

Zitieren

APA

Furie, R. A., Dall'Era, M., Vital, E. M., Garg, J. P., Irazoque Palazuelos, F., Zuta Santillán, A. E., Ravelo-Hernández, J., Santiago, M. B., Zazueta Montiel, B., Botha, S., Leszczyński, P., de Souza, V. A., Sicsik, S. A., Bellatin, L., Naidoo, A., Amoura, Z., D'Agostino, M. A., Kumar, S., Workeneh, B., …, & ALLEGORY Trial Investigators (2026). Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 395(3), 243-254. https://doi.org/10.1056/nejmoa2516150

Vancouver

Furie RA, Dall'Era M, Vital EM, Garg JP, Irazoque Palazuelos F, Zuta Santillán AE, et al. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine. 2026;395(3):243-254. doi:10.1056/nejmoa2516150

BibTeX
@article{Furie2026,
  author = {Furie, Richard A and Dall'Era, Maria and Vital, Edward M and Garg, Jay P and Irazoque Palazuelos, Fedra and Zuta Santillán, Adolfina E and Ravelo-Hernández, Jorge and Santiago, Mittermayer B and Zazueta Montiel, Beatriz and Botha, Stella and Leszczyński, Piotr and de Souza, Viviane Angelina and Sicsik, Sandra A and Bellatin, Luis and Naidoo, Asokan and Amoura, Zahir and D'Agostino, Maria Antonietta and Kumar, Sunil and Workeneh, Biruh and Rae, Julie and Mao, Huiyan A and Erblang, Felix and Meier, Oliver and Maller, Justine C and Askanase, Anca D and ALLEGORY Trial Investigators, ALLEGORY Trial Investigators},
  title = {Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {3},
  pages = {243--254},
  doi = {10.1056/nejmoa2516150}
}
Kostenlos starten →